Cytosorbents (CTSO) Projected to Post Earnings on Wednesday

Posted by on May 6th, 2026

Cytosorbents (NASDAQ:CTSO – Get Free Report) will likely be releasing its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect Cytosorbents to post earnings of ($0.06) per share and revenue of $9.40 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

Cytosorbents (NASDAQ:CTSO – Get Free Report) last posted its quarterly earnings data on Wednesday, March 25th. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04). Cytosorbents had a negative net margin of 22.12% and a negative return on equity of 150.53%. The business had revenue of $9.23 million for the quarter, compared to analysts’ expectations of $9.22 million. On average, analysts expect Cytosorbents to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cytosorbents Price Performance

CTSO opened at $0.61 on Wednesday. The business has a fifty day moving average of $0.66 and a 200 day moving average of $0.69. Cytosorbents has a 52-week low of $0.50 and a 52-week high of $1.39. The company has a quick ratio of 1.58, a current ratio of 2.13 and a debt-to-equity ratio of 2.82. The stock has a market cap of $37.94 million, a P/E ratio of -4.65 and a beta of 1.43.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CTSO. Citadel Advisors LLC grew its stake in Cytosorbents by 127.3% in the third quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock worth $61,000 after purchasing an additional 36,790 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Cytosorbents by 149.2% in the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after purchasing an additional 37,519 shares in the last quarter. CIBC Bancorp USA Inc. bought a new position in Cytosorbents in the third quarter worth approximately $161,000. Vanguard Group Inc. grew its stake in Cytosorbents by 3.7% in the third quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock worth $2,059,000 after purchasing an additional 79,535 shares in the last quarter. Finally, Avenir Corp grew its stake in Cytosorbents by 2.9% in the fourth quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock worth $3,343,000 after purchasing an additional 147,261 shares in the last quarter. Institutional investors own 32.87% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on CTSO. Weiss Ratings restated a “sell (e+)” rating on shares of Cytosorbents in a report on Wednesday, April 8th. D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a report on Thursday, March 26th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Cytosorbents presently has a consensus rating of “Hold” and a consensus price target of $5.38.

Get Our Latest Research Report on Cytosorbents

Cytosorbents Company Profile

(Get Free Report)

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.

Featured Stories

Earnings History for Cytosorbents (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.